Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.62 |
| ▸ | BACE1 | P56817 | 7/20 | 0.62 |
| ▸ | BCHE | P06276 | 5/20 | 0.62 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 1/20 | 0.54 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9785794 | 0.98 | ACHE (0.60) | ACHEBACE1BCHEDPP7SIGMAR1 | |
| Hydrochloric Acid SCHEMBL9785708 | 0.97 | ACHE (0.59) | ACHEBACE1BCHEDPP7SIGMAR1 | |
| SCHEMBL5754314 | 0.93 | ACHE (0.55) | ACHEBACE1BCHEDPP7SIGMAR1 | |
| SCHEMBL19077915 | 0.91 | BACE1 (0.64) | ACHEBACE1BCHEDPP7DRD4 | |
| SCHEMBL278467 | 0.91 | BACE1 (0.64) | ACHEBACE1BCHEDPP7DRD4 | |
| SCHEMBL19077916 | 0.91 | BACE1 (0.64) | ACHEBACE1BCHEDPP7DRD4 | |
| SCHEMBL5271846 | 0.86 | GAA (0.59) | ACHEBACE1BCHESIGMAR1MEN1 | |
| SCHEMBL13428738 | 0.86 | SIGMAR1 (0.54) | ACHEBACE1BCHESIGMAR1MEN1 | |
| SCHEMBL11282157 | 0.84 | ACHE (0.62) | ACHESIGMAR1KDM4EGAACCR3 | |
| SCHEMBL13428744 | 0.84 | CHRNB2 (0.63) | SIGMAR1KMT2AKDM4EDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2020-03-05 | — | — | US | disclosed |
| EP-3002287-B1 | Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors | NAT DEFENSE MEDICAL CENTER (TW) | 2018-01-31 | — | — | EP | disclosed |
| US-20170001958-A1 | INHIBITORS OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-05 | — | — | US | disclosed |
| EP-3002287-A1 | Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors | National Defense Medical Center (TW) | 2016-04-06 | — | — | EP | disclosed |
| WO-2015089360-A1 | INHIBITORS OF MITOCHNONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-06-18 | — | — | WO | disclosed |
| US-8927717-B1 | Thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2015-01-06 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20120115876-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | WARSHAKOON NAMAL CHITHRANGA (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115876-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | WARSHAKOON NAMAL CHITHRANGA (US) | 2012-05-10 | — | — | US | disclosed |
| US-8133894-B2 | N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones | AKEBIA THERAPEUTICS INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-02-03 | — | — | US | disclosed |
| WO-2005007645-A1 | SUBSTITUTED 4-AMINO-1-BENZYLPIPERIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040122014-A1 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004041806-A2 | SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | disclosed |
| US-5866589-A | Alkyl substituted piperadinyl and piperazinyl anti-AIDS compounds | PHARMACIA & UPJOHN COMPANY (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0625507-B1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| WO-1996018628-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-06-20 | — | — | WO | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122014-A1 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | CHRM2, CHRM1, CHRM3 | ACHE 409/4885BACE1 2547/4885BCHE 943/4885 |
| US-20120115876-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | IL17A, IFNG, CD4 | ACHE 2538/4885BACE1 2250/4885BCHE 1798/4885 |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, CYP51A1, CD4 | ACHE 2865/4885BACE1 1957/4885BCHE 2549/4885 |
| US-20170001958-A1 | INHIBITORS OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF | PDK4, PDK2, PDK3 | ACHE 4874/4885BACE1 4165/4885BCHE 4585/4885 |
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | CHRM5, CHRM3, CHRM1 | ACHE 378/4885BACE1 2624/4885BCHE 344/4885 |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | ACHE 1346/4885BACE1 2889/4885BCHE 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.